The interaction of Urocortin II and Urocortin III with amygdalar and hypothalamic cotricotropin-releasing factor (CRF) - reflections on the regulation of the hypothalamic-pituitary-adrenal (HPA) axis by Bagosi, Zsolt et al.
 1 
Full title: 
The interaction of Urocortin II and Urocortin III  
with amygdalar and hypothalamic cotricotropin-releasing factor (CRF)  
- reflections on the regulation of the hypothalamic-pituitary-adrenal (HPA) axis  
 
Authors: 
Zsolt Bagosi
1
, Krisztina Csabafi
1
, Miklós Palotai
1
, Miklós Jászberényi
1
,  
Imre Földesi
2
, János Gardi
2
, Gyula Szabó
1
, Gyula Telegdy
1,3
 
 
Affiliations: 
1 
Department of Pathophysiology, Faculty of Medicine, University of Szeged, Hungary 
2 
Department of Endocrinology, Faculty of Medicine, University of Szeged, Hungary 
3 
Neuroscience Research Group of the Hungarian Academy of Sciences, Szeged, Hungary 
 
Corresponding author:  
Zsolt Bagosi, MD, PhD 
Department of Pathophysiology, University of Szeged 
6725, Szeged, Semmelweis str. 1 
e-mail: bagosi@hotmail.com 
Tel: +3662545993 
Fax: +3662545710 
 
Short title: 
The interaction of Urocortin II and Urocortin III with CRF 
 
Keywords: 
urocortin II, urocortin III, CRF, corticosterone, HPA axis 
*Manuscript
Click here to view linked References
 2 
Abstract 
Urocortin II (Ucn III) and Urocortin III (Ucn III) are selective agonists of the CRF 
receptor type 2 (CRFR2). The aim of the present experiments was to investigate the effects of 
Ucn II and Ucn III on the central CRF and peripheral glucocorticoids in rats. Increasing doses 
(0.5-1-2-5 g/2 l) of Ucn II or Ucn III were administered intracerebroventricularly, then 
CRF concentration was determined by immunoassays in two different brain regions, the 
amygdala and the hypothalamus, and in two different time paradigms, 5 minutes and 30 
minutes after the administration of peptides. In parallel with the second determination, plasma 
corticosterone concentration was measured by chemofluorescent assay. The amygdalar CRF 
amount was increased significantly by 0.5 and 5 g of UCN II and 2 and 5 g of UCN III in 
the 5 minutes experiments and by 5 g of UCN II and 0.5 and 5 g of UCN III in the 30 
minutes experiments. The hypothalamic CRF content was not affected considerably in the 5 
minutes paradigm, but it was influenced significantly in the 30 minutes paradigm, with 0.5 
and 1 g of UCN II and 0.5 to 2 g of UCN III decreasing, and 2 and 5 g of UCN II and 5 
g of UCN III increasing the hormone concentration, respectively. The plasma corticosterone 
concentration was decreased by 1 and 2 g of UCN II and UCN III and increased by 0.5 and 5 
g of UCN III. The present results demonstrate that central administration of Ucn II and Ucn 
III modulate time-dependently and dose-dependently the amygdalar and the hypothalamic 
CRF concentration, and, directly or indirectly, the plasma corticosterone concentration. The 
present experiments suggest that the role of CRFR2 in the regulation of the HPA axis can be 
inhibitory or stimulatory, depending on the actual concentration of their agonists. 
 
Introduction 
The corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an 
extrahypothalamic neurotransmitter, which regulates the neuroendocrine, autonomic and 
behavioral responses to stressors through two distinct types of CRF receptors: CRFR1 and 
CRFR2 (Chang et al., 1993; Vale et al., 1981). Activation of CRFR1 was shown to induce 
stress reactions, while, until recently, activation of CRFR2 was thought to reduce stress 
responsiveness (Bale and Vale, 2004; Reul and Holsboer, 2002). The urocortins are members 
of the same CRF family of peptides, with similar chemical structure, but different 
pharmacological profile (Fekete and Zorrilla, 2007; Suda et al., 2004). Urocortin I (Ucn I) has 
equal affinity for both CRFRs (Vaughan et al., 1995); Urocortin II (Ucn II) and Urocortin III 
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(Ucn III) have much higher affinity for CRFR2, than CRFR1 (Lewis et al., 2001; Reyes et al., 
2001). Therefore, these two peptides are considered selective agonists for CRFR2. 
CRF is the principal activator of the hypothalamic-pituitary adrenal (HPA) axis 
(Carrasco and Van de Kar, 2003; Tsigos and Chrousos, 2002). Various stressors activate 
different sources of CRF, such as the central nucleus of the amygdala (CeA) and the 
paraventricular nucleus of the hypothalamus (PvN). CRF, in synergy with arginine-
vasopressin (AVP), stimulates the secretion of the adrenocorticotrophic hormone (ACTH) 
from the anterior pituitary, which, in turn, stimulates the production of the glucocorticoids in 
the adrenal cortex. Therefore, the increase glucocorticoid concentration in the plasma reflects 
the activation of the HPA axis, but it also exerts a negative feedback effect on the 
hypothalamic CRF and a positive feedback effect on the amygdalar CRF production. 
Nevertheless, amygdalar CRF may stimulate the hypothalamic CRF release through a feed-
forward effect; this represents the limbic activation of the HPA axis (Herman et al., 2005; 
Jankord and Herman, 2008). 
Previous studies demonstrated that CRF and UCN I stimulate the HPA axis in rodents 
by activating CRFR1, which are expressed abundantly in the central nervous system (CNS), 
especially in the cerebral cortex and the anterior pituitary (Skelton et al., 2000; Turnbull and 
Rivier, 1997; Vale et al., 1981; Vaughan et al., 1995). Other studies suggested that activation 
of CRFR2 inhibits the HPA axis, CRFR2 being distributed predominantly in the periphery 
and limited centrally in the amygdalar and the hypothalamic nuclei (Valdez et al., 2002; 
Valdez et al., 2003). However, recently it was shown that administration of UCN II and UCN 
III, that is the activation of CRFR2 stimulates the HPA axis in rats (Jamieson et al., 2006; 
Maruyama et al., 2007). Moreover, it seems that the participation of CRFR2 in the regulation 
of the HPA axis is stressor-specific (physical vs. psychological) and species-specific (mice vs. 
rats).  
The aim of the present experiments was to investigate the effects of Ucn II and Ucn III 
on the central CRF and peripheral glucocorticoids in rats. UCN II or UCN III was 
administered into the lateral cerebral ventricle of the rat and CRF concentration was measured 
in two different brain regions: the amygdala and the hypothalamus. The hormone 
concentrations were determined by immunoassays in two different time paradigms: 5 minutes 
and 30 minutes after the intracerebroventricular (icv) administration of the peptides. In 
parallel with the second determination, the plasma corticosterone concentration was 
determined by a chemofluorescent assay. 
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Materials and methods 
 
Animals 
Male Wistar rats (N = 106) weighing 150-200 g were used. During the experiments 
they were kept and handled in accordance with the instructions of the University of Szeged 
Ethical Comittee for the Protection of Animals in Research. The animals were housed in their 
home cages at constant room temperature (23 °C) on a standard illumination schedule, with 
12-h light and 12-h dark periods (lights on from 6:00 a.m.). Commercial food and tap water 
were available ad libitum. The animals were allowed to acclimatize for at least 7 days before 
surgery, and they were handled daily to minimize the effects of nonspecific stress. 
 
In vivo cannulation 
Under intraperitoneal anesthesia with Phenobarbital 35 mg/kg (Nembutal, CEVA-
Phylaxia, Hungary), the rats were implanted with a stainless steel Luer cannula (10 mm long) 
aimed at the right lateral cerebral ventricle. The cannula was secured to the skull with dental 
cement and acrylate. The lateral cerebral ventricle was targeted according to the Stereotaxic 
Atlas of the Rat Brain (Pellegrino et al., 1979): 0.2 mm posterior to the bregma, 1.7 mm 
lateral to the bregma and 3.7 mm deep from the dural surface. The animals were allowed at 
least 5 days to recover after the surgery and the permeability of the cannula was tested with 
methylene blue after the experiments. 
 
Treatments 
The animals (N=60) were treated through the cannula implanted into the right lateral 
cerebral ventricle. Saline solution (2 l NaCl 0.9 %, Biogal, Hungary) was administered for 
the control groups and increasing doses (0.5, 1, 2 and 5 g/2 l) of UCN II (Bachem Ltd, 
Switzerland) or UCN III (Bachem Ltd, Switzerland) were injected for the peptide-treated 
groups. The saline solution and the UCNs were administered between 8:00-10:00 a.m. to 
avoid circadian changes of the central and peripheral hormones of the HPA axis. Two sets of 
experiments were performed. In the first one the animals were decapitated 5 minutes after 
treatment, their brains were removed and their amygdalae and their hypothalami were isolated 
and homogenised for determination of CRF concentration. In the second set, the animals were 
sacrificed 30 minutes after treatment, their brains were processed likewise and their trunk 
blood was collected for plasma corticosterone determination. 
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In vitro homogenisation 
Brain tissues were dissected in a Petri dish filled with ice-cold Krebs solution 
(composition: 113 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 25 mM NaHCO3, 11.5 mM 
glucose, 1.2 mM KH2PO4, 2.5 mM CaCl2, pH 7.4, Reanal, Hungary). Both the amygdalae and 
the hypothalami were isolated according to the Stereotaxic Atlas of the Rat Brain (Pellegrino 
et al., 1979), with the bregma as point of reference. The coordinates were as follows: 
rostrocaudal 0 - -2 mm, mediolateral +3 - +6 mm, and dorsoventral +7 - +10 mm for the 
amygdala; rostrocaudal +2.6 - -2.6 mm, mediolateral +1.5 - -1.5 mm, and dorsoventral  +7 - 
+10 mm for the hypothalamus. The brain tissues were homogenised following the instructions 
of Suda and Joanny (Joanny et al., 1989; Suda et al., 1985). 
 
CRF determination 
For determination of the amygdalar and hypothalamic CRF contents, we used the 
mouse/rat CRF high-sensitivity Enzyme-Linked Immuno-Sorbent Assay (ELISA) kit 
provided by CosmoBio Company, Ltd., Japan. This kit is based on a sandwich ELISA and 
shows no cross-reactivity to UCNs (mouse/rat or human). 
 
Corticosterone determination 
The plasma corticosterone was extracted and detected by the chemofluorescent assay 
described by Zenker and Bernstein, as modified by Purves and Sirett (Purves and Sirett, 1965; 
Zenker and Bernstein, 1958).  
 
Statistics 
Statistical analysis of the results and data reduction were performed by analysis of 
variance (ANOVA, SigmaPlot Software). The differences between groups were tested by 
one-way ANOVA followed by Holm-Sidak post hoc comparison test. A probability level of 
0.05 or less was accepted as indicating a statistically significant difference. 
 
Results 
UCN II produced significant augmentations of the amygdalar CRF amount in the 5 
minutes and in the 30 minutes experiments (Figure 1). 0.5 and 5 g of UCN II were the most 
effective doses in the first set of experiments [F(4,30) = 14.118, p<0.001], but only the effect 
of the highest dose was effective in the second set of experiments F(4,30) = 16,112, p<0.001].  
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UCN II did not influence the hypothalamic CRF content in the 5 minutes experiments. 
In contrast, it induced dose-dependent changes of the hypothalamic CRF content in the 30 
minutes experiments. 0.5-2 g of UCN II decreased, while 5 g of UCN II increased the 
hormone concentration, respectively [F(4,30) = 40.200, p<0.001] (Figure 2).  
The plasma corticosterone concentration was also changed dose-dependently, with the 
1 and 2 g of UCN II decreasing it significantly [F(4,30) = 14.118, p<0.001], at 30 minutes 
following the administration of the peptide (Figure 3). 
UCN III induced significant augmentation of the amygdalar CRF amount in both the 
5-minutes and the 30 minutes paradigm [F(4,30) = 20.459, p<0.001]. In the first set of 
experiments 2 and 5 g, in the second set of experiments 0.5 and 5 g of the peptide produced 
significant effects [F(4,30) = 25,825, p<0.001] (Figure 4). 
UCN III did not induce any changes in the hypothalamic CRF content in the 5 minutes 
paradigm. Although UCN III influenced dose-dependently the hypothalamic CRF content in 
the 30 minutes paradigm: low peptide doses (0.5 and 1 g) decreased, high peptide doses 
increased the hormone concentration significantly [F(4,30) = 158.254, p<0.001] (Figure 5). 
The plasma corticosterone concentration was influenced in a dose-dependent manner 
also. It was increased significantly by 0.5 and 5 g of UCN III and decreased significantly by 
1 and 2 g of UCN III [F(4,30) = 21,788, p<0.001], respectively, both determined 30 minutes 
following the administration of the peptide (Figure 6). 
 
Discussion 
The present study demonstrates that central Ucn II and Ucn III interacts with the 
amygdalar and the hypothalamic CRF production in a time-dependent manner. Our results 
coincides with previous reports, according to which UCN II and UCN III induces changes in 
CRF and/or AVP hnRNA and/or mRNA expression (Jamieson et al., 2006; Maruyama et al., 
2007). One study showed that icv administration of similar doses of UCN II and UCN III 
increased the expression of the hypothalamic CRF hnRNA and AVP hnRNA after 30 minutes 
in the PvN of Wistar rats (Maruyama et al., 2007). Another study proved that icv 
administration of both low and high doses of UCN III induced hypothalamic expression of 
AVP mRNA, but not CRF mRNA in Sprague-Dawley rats after 4 hours, though it did not 
exclude the possibility of interaction of UCN III with either CRF or AVP earlier than 4 hours 
(Jamieson et al., 2006). Based on the present results, we presume that central activation of 
CRFR2 in the amygdala inhibits the CRF release (from the 5 minutes experiments), then 
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further inhibits the CRF release or stimulates the amygdalar CRF synthesis (from the 30 
minutes experiments), at least, in the presence of the high concentrations of their agonists. 
Central administration of CRFR2 agonists first does not influence the hypothalamic CRF 
release (in the 5 minutes experiments), then it stimulates the hypothalamic CRF synthesis or 
inhibits the hypothalamic CRF release (in the 30 minutes experiments), in most of the doses 
of UCNs used, except the highest dose of UCN II. We suppose that the increase of the 
hypothalamic CRF concentration in this case may be due to the feed-forward effect achieved 
by the increased amygdalar CRF secretion on the paraventricular CRF production. 
The present study also demonstrates that the CRFR2 agonists acts on the adrenal 
glucocorticoid secretion in a dose-dependent manner. The results of the present study may 
seem confusing, as UCN II and UCN III have different, even opposite impacts on the plasma 
corticosterone concentration. Actually, previous studies also reflect this dichotomy. On one 
hand, experiments with mice suggested that activation of CRFR2 stimulates the HPA axis and 
mediates anxiolitic and antidepressive effects (Bale et al., 2000; Kishimoto et al., 2000). On 
the other hand, experiments with rats demonstrated that administration of CRFR2 agonists 
activates the HPA axis and promotes anxiogenic and depressive behavior (Jamieson et al., 
2006; Maruyama et al., 2007). Moreover, a third group of experiments resulted in lack of 
neuroendocrine (Pelleymounter et al., 2004) or behavioral responses (Zhao et al., 2007) 
following central administration of UCN II and UCN III in rodents. However, the 
contradictions raised can be explained by the dose-dependent actions of Ucn II and Ucn III. 
We observed that intermediate doses of CRFR2 agonists decrease and lower or higher doses 
of CRFR2 agonists increase or do not change the plasma corticosterone concentrations. We 
propose that these dose-dependent changes are modulated by the time-dependent changes of 
the amygdalar and hypothalamic CRF synthesis/release. The only exception to this premise is 
represented by the lowest dose of UCN III, the effect of which can be explained by the 
participation of another ACTH secretagogue, such as paraventricular AVP (Jamieson et al., 
2006; Maruyama et al., 2007). The increased corticosterone concentration in this case is 
associated with an increased amygdalar CRF and a decreased hypothalamic CRF 
concentration, which may be caused by the positive and negative feedback effects exerted by 
plasma glucocorticoids on the amygdalar and paraventricular CRF production, respectively. 
(Fekete and Zorrilla, 2007; Suda et al., 2004).  
In our previous experiments, increased brain CRF (2-4 ng/ml) and plasma 
corticosterone concentration (25-45 g/100 ml) have been measured in rats exposed to non-
specific stress. Icv administration of UCN II and UCN III induced a similarly significant 
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response. However, different stressors may activate different brain regions (the basolateral 
nucleus of the amygdala or the PvN of the hypothalamus) (Sajdyk et al., 2004; Skorzewska et 
al., 2011), resulting in the elevation of plasma corticosterone concentration, which, in turn, 
can influence bidirectionally the amygdalar CRF and hypothalamic CRF concentration 
(Herman et al., 2005; Jankord and Herman, 2008). Moreover, these brain regions may present 
distinct CRFR distributions and reciprocal afferentations. Therefore, the participation of 
CRFR1 or CRFR2 in the regulation of the HPA axis is not a matter of simple dualism, but 
varies according to the specific brain regions and/or neuron subpopulations involved in the 
stress response (Janssen and Kozicz, 2013). 
Taking the previous and the present results into consideration, we conclude that 
central administration of Ucn II and Ucn III modulate time-dependently and dose-dependently 
the amygdalar and the hypothalamic CRF concentration, and, directly or indirectly, the 
plasma corticosterone concentration. Consequently, the role of CRFR2 in the regulation of the 
HPA axis can be inhibitory or stimulatory, depending on the actual concentration of their 
agonists. 
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Legends for figures 
 
Figure 1. The effects of UCN II on the amygdalar CRF concentration determined 5 minutes 
and 30 minutes following the icv administration of the peptide. Values are presented as means 
± SEM; * indicates a statistically significant difference (p<0.05). 
 
Figure 2. The effects of UCN II on the hypothalamic CRF concentration determined 5 
minutes and 30 minutes following the icv administration of the peptide. Values are presented 
as means ± SEM; * indicates a statistically significant difference (p<0.05). 
 
Figure 3. The effects of UCN II on the plasma corticosterone concentration determined 30 
minutes following the icv administration of the peptide. Values are presented as means ± 
SEM; * indicates a statistically significant difference (p<0.05). 
 
Figure 4. The effects of UCN III on the amygdalar CRF concentration determined 5 minutes 
and 30 minutes following the icv administration of the peptide. Values are presented as means 
± SEM; * indicates a statistically significant difference (p<0.05). 
 
Figure 5. The effects of UCN III on the hypothalamic CRF concentration determined 5 
minutes and 30 minutes following the icv administration of the peptide. Values are presented 
as means ± SEM; * indicates a statistically significant difference (p<0.05). 
 
Figure 6. The effects of UCN III on the plasma corticosterone concentration determined 30 
minutes following the icv administration of the peptide. Values are presented as means ± 
SEM; * indicates a statistically significant difference (p<0.05). 
 
Figure legends
